Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling

Hypertension Research

Volumn 28, Issue 7, 2005, Pages 593-600

  Takai, Shinji ^a   Kirimura, Kazuyoshi ^a,b   Jin, Denan ^a   Muramatsu, Michiko ^a   Yoshikawa, Katsuhiro ^a   Mino, Yoshiki ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b BILIS   (Japan)

Author keywords

Angiotensin II receptor blocker; Lipophilicity; NAD(P)H oxidase; Nitric oxide

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOSARTAN; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LIPOPHILICITY; MALE; NONHUMAN; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PROTEIN EXPRESSION; RAT; RAT STRAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; VASODILATATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BODY WEIGHT; CAROTID ARTERY DISEASES; GENE EXPRESSION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LIPIDS; LOSARTAN; MALE; MEMBRANE TRANSPORT PROTEINS; MYOCARDIUM; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; ORGAN SIZE; PHOSPHOPROTEINS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENIN; VASODILATION;

EID: 25844490022     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.28.593     Document Type: Article

References (38)

1. Unger T, Culman J, Gohlke P: Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens Suppl 1998; 16: S3-S9.
2. Wienen W, Entzeroth M, van Meel JC, et al: A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127-156.
3. Unger T, Ganten D, Lang RE, Scholkens BA: Persistent tissue converting enzymeinhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1985; 7: 36-41.
4. Miyazaki M, Kawamoto T, Okunishi H: Vascular affinity of trandolapril. Am J Hypertens 1995; 8: 63S-67S.
5. Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E: Mortality rates inelderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141: 102-112.
6. Takai S, Jin D, Sakaguchi M, Miyazaki M: Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens Res 2004; 27: 213-219.
7. Jin D, Ueda H, Takai S, et al: Effect of chymase inhibition on the arteriovenous fistula stenosis in dog. J Am Soc Nephrol 2005; 16: 1024-1034.
8. phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45-51.
9. Ulker S, McMaster D, McKeown PP, Bayraktutan U: Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovasc Res 2003; 59: 488-500.
10. Hamilton CA, Brosnan MJ, Al-Benna S, Berg G, Dominiczak AF: NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 2002; 40: 755-762.
11. Brosnan MJ, Hamilton CA, Graham D, Lygate CA, Jardine E, Dominiczak AF: Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 2002; 20: 281-286.
12. van der Giet M, Erinola M, Zidek W, Tepel M: Captopril and quinapril reduce reactive oxygen species. Eur J Clin Invest 2002; 32: 732-737.
13. Pitt B, Poole-Wilson PA, Segal R, et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
14. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
15. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
16. Julius S, Kjeldsen SE, Weber M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
17. McInnes GT: Angiotensin II antagonism in clinical practice: experience with valsartan. J Cardiovasc Pharmacol 1999; 33 (Suppl 1): S29-S32.
18. Stopher DA, Beresford AP, Macrae PV, Humphrey MJ: The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S55-S59.
19. Burnier M, Maillard M: The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001; 1 (Suppl): 6-11.
20. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-649.
21. 1 receptor blocker olmesartan. Hypertension 2004; 43: 263-269.
22. Hashimoto Y, Kurosawa Y, Minami K, Fushimi K, Narita H: A novel angiotensin II-receptor antagonist, 606A, induces regression of cardiac hypertrophy, augments endothelium-dependent relaxation and improves renal function in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol 1998; 76: 185-192.
23. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA: Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 1999; 33: 1353-1358.
24. Kimoto-Kinoshita S, Nishida S, Tomura TT: Decrease of endothelial nitric oxide synthase in stroke-prone spontaneously hypertensive rat cerebral cortex. Neurosci Lett 2000; 288: 103-106.
25. Tanabe A, Naruse M, Seki T, et al: Gene expression of endothelin-1 and endothelial-type nitric oxide synthase in cardiovascular tissues of stroke-prone spontaneously hypertensive rats/Izm: effects of the angiotensin-converting enzyme inhibitor aracepril. J Cardiovasc Pharmacol 1998; 31 (Suppl 1): S395-S398.
26. Umemoto S, Tanaka M, Kawahara S, et al: Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res 2004; 27: 877-885.
27. Vaziri ND, Ni Z, Oveisi F: Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension 1998; 31: 1248-1254.
28. Crabos M, Coste P, Paccalin M, et al: Reduced basal NO-mediated dilation and decreased endothelial NO-synthase expression in coronary vessels of spontaneously hypertensive rats. J Mol Cell Cardiol 1997; 29: 55-65.
29. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK: Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406-413.
30. Ying CJ, Xu JW, Ikeda K, Takahashi K, Nara Y, Yamori Y: Tea polyphenols regulate nicotinamide adenine dinucleotide phosphate oxidase subunit expression and ameliorate angiotensin II-induced hyperpermeability in endothelial cells. Hypertens Res 2003; 26: 823-828.
31. phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 981-987.
32. phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002; 90: 1205-1213.
33. Takai S, Sakonjo H, Miyazaki M: Beneficial effect of trandolapril on the lifespan of a severe hypertensive model. Hypertens Res 2001; 24: 559-564.
34. Morishita R, Higaki J, Nakamura F, et al: Regression of hypertension-induced vascular hypertrophy by an ACE inhibitor and calcium antagonist in the spontaneously hypertensive rat. Blood Press Suppl 1992; 3: 41-47.
35. Fernandez-Alfonso MS, Kreutz R, Zeh K, Liu Y, Ganten D, Paul M: Differential regulation of vascular angiotensin I-converting enzyme in hypertension. Hypertension 1994; 24: 280-286.
36. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D: Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998; 20: 205-221.
37. Mizuno K, Niimura S, Katoh K, Fukuchi S: TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats. Life Sci 1994; 54: 1987-1994.
38. Izumi Y, Kim S, Murakami T, Yamanaka S, Iwao H: Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats. Hypertension 1998; 31: 50-56.